----item----
version: 1
id: {BB5113ED-E1EA-48ED-B5F8-A6C19E5AA461}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/08/24/Sunovions Seizure Drug Aptiom Wins Monotherapy Use
parent: {D37D02A2-D786-4924-A7F9-DF194032F233}
name: Sunovions Seizure Drug Aptiom Wins Monotherapy Use
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 6ad387b2-37ee-4e32-b15c-6d4d91a0fe22

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 51

Sunovion's Seizure Drug Aptiom Wins Monotherapy Use
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 50

Sunovions Seizure Drug Aptiom Wins Monotherapy Use
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1304

<p>Marlborough, Massachusetts-based Sunovion Pharmaceuticals won the FDA's approval to market Aptiom (eslicarbazepine acetate) as monotherapy to treat partial-onset seizures. </p><p>The drug initially was approved in 2013 as adjunctive therapy for partial-onset seizures.</p><p>The FDA nod to the supplemental new drug application makes Aptiom the only once-daily non-extended release antiepileptic drug (AED) on the US market, which can be used alone or in combination with other AEDs to treat partial-onset seizures. </p><p>In the US, more than one million people live with uncontrolled seizures.</p><p>Aptiom's monotherapy approval was based on the results of two identically designed Phase III studies, which, along with other data, confirmed the drug was effective and well-tolerated at a daily dose range of 800mg to 1,600mg. </p><p>Both trials met the pre-specified primary endpoint of percentage of patients who exited the study due to pre-defined criteria identifying worsening seizure control, versus historical controls from previous, similarly designed trials of epilepsy patients converting to AED monotherapy.</p><p>The most common treatment-related adverse events, headache, dizziness, fatigue, somnolence, and nausea, were mainly mild or moderate in severity. </p><p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 179

<p>Marlborough, Massachusetts-based Sunovion Pharmaceuticals won the FDA's approval to market Aptiom (eslicarbazepine acetate) as monotherapy to treat partial-onset seizures. </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 50

Sunovions Seizure Drug Aptiom Wins Monotherapy Use
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150824T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150824T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150824T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029629
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 51

Sunovion's Seizure Drug Aptiom Wins Monotherapy Use
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

pdfNewsLetter
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

360078
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042442Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

6ad387b2-37ee-4e32-b15c-6d4d91a0fe22
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042442Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
